NCT04476277View on ClinicalTrials.gov

Red Cell Half Life Determination in Patients With and Without Sickle Cell Disease

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

April 19, 2021

Primary Completion Date

December 20, 2022

Study Completion Date

February 14, 2023

Conditions
Sickle Cell DiseaseSickle Cell Anemia
Interventions
DRUG

Biotin label

Autologous cells will be collected and biotin-labeled ex vivo and reinfused to measure red cell survival

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH